Janice Schakowsky actually said...
340B is not the driver of high drug prices. The pharmaceutical corporations' unlimited power to set the list price is the driver.
Context
Schakowsky argues that pharmaceutical companies, not the 340B program, are responsible for high drug prices.
07/10/2018